Your gift is 100% tax deductible
Improving Quality of Life for Lung Cancer Survivors
Study leads to a clinical trial of virtual sessions to help people with early-stage lung cancer successfully transition from treatment to follow-up care.
The Challenge
For some people with cancer, the need for treatment and supportive care continues for a long time. Even when the goal of treatment is to cure the cancer, finishing treatment does not mean that a patient’s cancer experience is over. Depending on the type of cancer, patients will have a range of supportive care needs as they transition from active treatment to routine follow-up care (also known as surveillance care).
While there are studies describing what patients most need during this transition, people with lung cancer rarely are included in these quality-of-life (QoL) studies. Thus, their supportive care needs remain a grey area. Research to better understand those needs can inform cancer programs and providers to help patients set the stage for survivorship with coping strategies that address their specific concerns.
The Research
Massachusetts General Hospital recently funded a pilot study of a supportive care intervention for patients who have completed treatment for lung cancer. Results of this study were published in an??at the 2021?American Society of Clinical Oncology Quality Care Symposium. American Cancer Society (草莓影视) did not fund the study, but three of the four abstract authors are current or previous 草莓影视 grantees: Lara Traeger, PhD, Joseph Greer, PhD, and Jennifer Temel, MD. (See information about their grants below.)
A primary goal of my research is to develop and evaluate the impact of supportive care interventions that are tailored to the needs of patients with cancer and their caregivers throughout their illness trajectory. I’m using innovative delivery modalities, including mobile apps, video tools, and telehealth, to make supportive care interventions accessible outside of the cancer clinic for patients and their caregivers. In this pilot study with my Massachusetts General Hospital colleagues, we tested the feasibility and acceptability of virtual visits for patients with lung cancer to help achieve their best possible quality of life after their treatments had ended.”
The researchers interviewed patients about their quality of life after their lung cancer treatments had ended.?Then, they used these findings to develop and refine a program to support survivors during the transition from treatment to follow-up care – ensuring that the program addressed the challenges and concerns that patients had described.
According to the findings from the study, after curative treatment for lung cancer, patients:
- Faced unexpected challenges in coping with residual symptoms
- Felt uncertain about their future health
- Experienced changes in access to social support
The colleagues co-developed a 5-session, virtual intervention, delivered via phone or video chat.?The sessions used a coping skills framework that balanced acceptance- and change-oriented approaches.
Patients who participated in the study said they valued the opportunity to validate their experiences, address current challenges, and cope with difficult emotions.
Although their feedback indicated that timing of the intervention (3 weeks after cancer treatments ended) and its content targeted the patients’ needs and concerns, results suggested that further refinement might enhance their use of new skills.
Jennifer Temel, MD, is an American Cancer Society Clinical Research Professor (grant term 9/1/2020 to 8/31/2025). Her grant project focuses on ensuring the delivery of high-quality care for patients with cancer.
Lara Traeger, PhD, had two grants (1/1/2011 to 12/31/2013 and 7/1/14 to 12/31/2019) related to depression and mental health in cancer patients that lead to a of an intervention to help manage cancer pain.
Joseph Greer, PhD, had a grant (1/1/2013 to 12/31/2017) for studying web-based cognitive behavioral therapy for anxiety in patients with incurable cancer that also led to a .
Why It Matters?
This pilot study demonstrated the value of the program’s framework and virtual delivery—which supports scalability for survivors of lung cancer regardless of their location. The success of this pilot study helped lead to a , led by Lara Traeger, PhD.